Boehringer Loses Bad Faith Claim In Diabetes Drug Deal Suit
A London judge has sided with Royalty Pharma in its €23 million ($26.6 million) claim against Boehringer Ingelheim International GmbH, finding the patent licensing company did not change the basis on...To view the full article, register now.
Already a subscriber? Click here to view full article